ClinicalTrials.Veeva
Menu

Find clinical trials for Kidney Disease in Sevilla, AN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Kidney Diseases
Chronic Renal Insufficiency
Chronic Kidney Failure
Renal Insufficiency
IGA Glomerulonephritis
Renal Cell Carcinoma
Diabetes Mellitus

Kidney Disease trials near Sevilla, AN, ESP:

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney...

Enrolling
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Drug: Tolvaptan (OPC-41061)

Phase 3

Otsuka
Otsuka

Sevilla, Spain and 17 other locations

to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...

Enrolling
Chronic Kidney Disease With High Proteinuria
Drug: Zibotentan/Dapagliflozin
Drug: Dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

Sevilla, Spain and 324 other locations

compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effec...

Enrolling
Chronic Kidney Disease
Drug: Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg
Drug: Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg

Phase 2

AstraZeneca
AstraZeneca

Sevilla, Spain and 94 other locations

tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...

Enrolling
Proteinuric Kidney Disease
Drug: Placebo
Drug: VX-147

Phase 2, Phase 3

Vertex Pharmaceuticals
Vertex Pharmaceuticals

Seville, Spain and 236 other locations

Locations recently updated

Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys...

Enrolling
Chronic Kidney Disease
Type 1 Diabetes Mellitus
Other: Placebo
Drug: Finerenone

Phase 3

Bayer
Bayer

Castilleja de la Cuesta, Spain and 80 other locations

Locations recently updated

The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the cl...

Enrolling
Chronic Kidney Disease
Cardiac Disease
Drug: Placebo
Drug: Ravulizumab

Phase 3

Alexion Pharmaceuticals
Alexion Pharmaceuticals

Sevilla, Spain and 176 other locations

Locations recently updated

receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD.Empagliflozin lowers blood...

Enrolling
Chronic Kidney Disease
Type 2 Diabetes Mellitus
Drug: Finerenone (BAY94-8862 ) 20 mg
Drug: Finerenone Placebo

Phase 2

Bayer
Bayer

Castilleja de la Cuesta, Spain and 210 other locations

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...

Enrolling
Chronic Kidney Disease
Proteinuria
Drug: Finerenone (Kerendia, BAY94-8862)

Phase 3

Bayer
Bayer

Sevilla, Spain and 141 other locations

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...

Enrolling
Chronic Kidney Disease
Proteinuria
Drug: Placebo
Drug: Finerenone (Kerendia, BAY94-8862)

Phase 3

Bayer
Bayer

Sevilla, Spain and 147 other locations

function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The st...

Enrolling
Overweight or Obesity
CKD
Drug: LY3437943
Drug: Placebo

Phase 2

Lilly
Lilly

Sevilla, Spain and 35 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems